xRead - September 2022

Wise et al.

Page 314

Author Manuscript Author Manuscript Author Manuscript Author Manuscript

Study Year LOE Study design Study groups Clinical endpoint Conclusion 2 Placebo (n = 273) 1 SCIT (n = 41); RQLQ, symptoms score, medication score

QOL significantly affected by AR. SCIT improves RQLQ, symptom and medication scores.

SF-36, RQLQ Levocetirizine improves QOL and decreases disease-related costs. RQLQ, problem free days

Enzyme potentiated desensitization does not improve QOL compared to placebo.

Gerth Van Wijk et al. 694 2000 1b RCT AR and nasal capsaicin (n = 26) VAS, RQL Capsaicin does not sufficiently control rhinitis symptoms. Juniper et al. 671 1991 1b RCT, double-blind AR questionnaire development (n = 85); validation (n = 60) RQLQ In addition to local symptoms, patients experience impaired QOL through systemic, sleep, emotional symptoms, and practical/activity limitations. Beclomethasone use correlated to RQLQ. Linneberg et al. 667 2016 2a SR AR QOL Patients with AR suffer from decreased QOL in terms of both physical and mental health. Hahn-Pedersen et al. 668 2014 2a SR AR QOL AR patients have significantly worse general and disease-specific QOL with physical, practical, and activity domains most affected. SCIT improves QOL and symptoms. Filanowicz et al. 695 2016 2b Observational cohort SCIT (n = 200): 1 Allergic asthma (n = 101); 2 AR (n = 99) RQLQ QOL is significantly affected by AR. SCIT significantly improved QOL in asthma and AR. Jaruvongvanich et al. 684 2016 2b Observational cohort AR (n = 260) SF-12, TSS Extranasal symptoms in AR correlate with physical and mental health QOL domains. Bousquet et al. 681 2013 2b Observational cross-sectional

AR (n = 990) VAS, RQLQ, TSS 20% mild intermittent, 17% mild persistent, 15% moderate-severe intermittent, 48% moderate severe persistent. Severity and duration of AR impact on QOL. Ocular symptoms impact RQLQ more than nasal obstruction. Sneezing/rhinorrhea do not impact RQLQ.

2 Control (n = 19)

1 Levocetirizine (n = 278); 2 Placebo (n = 273)

1 Enzyme potentiated desensitization (n = 90); 2 Placebo (n = 93)

Colas et al. 679 2006 1b RCT, double-blind AR (n = 60):

Bachert et al. 675 2004 1b RCT, double-blind PAR (n = 551):

Radcliffe et al. 693 2003 1b RCT, double-blind SAR (n = 183):

Int Forum Allergy Rhinol . Author manuscript; available in PMC 2020 June 10.